Review of Hydroxypropyl Methylcellulose in Artificial Tears for the Treatment of Dry Eye Disease

Dry eye disease (DED) is a highly prevalent condition, resulting in reduced quality of life, lower participation in social life and impaired work efficiency. Hydroxypropyl methylcellulose (HPMC) is a cellulose‐based viscosity‐enhancing agent and is one of the most popular therapeutic ingredients in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta ophthalmologica (Oxford, England) England), 2024-12, Vol.102 (8), p.881-896
Hauptverfasser: Mysen, O. Martin B., Hynnekleiv, Leif, Magnø, Morten S., Vehof, Jelle, Utheim, Tor P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 896
container_issue 8
container_start_page 881
container_title Acta ophthalmologica (Oxford, England)
container_volume 102
creator Mysen, O. Martin B.
Hynnekleiv, Leif
Magnø, Morten S.
Vehof, Jelle
Utheim, Tor P.
description Dry eye disease (DED) is a highly prevalent condition, resulting in reduced quality of life, lower participation in social life and impaired work efficiency. Hydroxypropyl methylcellulose (HPMC) is a cellulose‐based viscosity‐enhancing agent and is one of the most popular therapeutic ingredients in artificial tears. This review aims to evaluate the literature on the efficacy and safety of HPMC used in the treatment of DED. Literature searches were conducted in PubMed and Cochrane CENTRAL. A total of 28 clinical trials from 26 publications are included in this review, including 21 clinical intervention studies evaluating the effect of HPMC treatment over time and seven single instillation studies evaluating the short‐term physical and symptomatic effects of HPMC after drop‐instillation. The duration of clinical intervention studies ranged from 2 weeks to 5.5 months. DED severity ranged from mild to severe. Drop frequency ranged from two to up to 16 drops per day. HPMC concentration in artificial tears ranged from 0.2% to 0.5%. No major complications or adverse events were reported. Artificial tears containing HPMC were effective at improving symptoms and some signs of DED. However, combination drops with HPMC plus other therapeutic ingredients seem more effective than HPMC alone. HPMC appears to be equally effective or inferior to hyaluronic acid (HA). There is no evidence of superiority or inferiority to either carboxymethylcellulose (CMC) or polyethylene glycol 400/propylene glycol (PEG/PG). No single study explained the choice of drop frequency or HPMC concentration. More well‐designed studies are needed to determine an evidence‐based standard for HPMC treatment, including drop frequency, concentration and molecular weight for different DED severity and subgroups.
doi_str_mv 10.1111/aos.16753
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3099857777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3099857777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2783-1640c07fd67d3d539f8bc2ae8e662e299d2b61ff7fd3e16edd2ccacfca7b39673</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMoWqsL_4AE3OiiNY9OMrMsbX2AImgFdzHN3GDKtKnJjDr_3tSqC8GzuXfx8XE4CB1R0qcp59rHPhUy41uoQ2WW9bgU-fbvnz3tof0Y54QIKsRgF-3xgtGCDEgHPd_Dm4N37C2-asvgP9pV8Ku2wrdQv7SVgapqKh8BuyUehtpZZ5yu8BR0iNj6gOsXwNMAul7Asl5rxqHFkxbw2EXQEQ7QjtVVhMPv20WPF5Pp6Kp3c3d5PRre9AyTOe9RMSCGSFsKWfIy44XNZ4ZpyEEIBqwoSjYT1NpEcKACypIZo401Ws54ISTvotONN_V_bSDWauHiur5egm-i4qQo8kymJPTkDzr3TVimdopTJqRkGaGJOttQJvgYA1i1Cm6hQ6soUevZVZpdfc2e2ONvYzNbQPlL_uycgPMN8O4qaP83qeHdw0b5Cfr-jN0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126772501</pqid></control><display><type>article</type><title>Review of Hydroxypropyl Methylcellulose in Artificial Tears for the Treatment of Dry Eye Disease</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Mysen, O. Martin B. ; Hynnekleiv, Leif ; Magnø, Morten S. ; Vehof, Jelle ; Utheim, Tor P.</creator><creatorcontrib>Mysen, O. Martin B. ; Hynnekleiv, Leif ; Magnø, Morten S. ; Vehof, Jelle ; Utheim, Tor P.</creatorcontrib><description>Dry eye disease (DED) is a highly prevalent condition, resulting in reduced quality of life, lower participation in social life and impaired work efficiency. Hydroxypropyl methylcellulose (HPMC) is a cellulose‐based viscosity‐enhancing agent and is one of the most popular therapeutic ingredients in artificial tears. This review aims to evaluate the literature on the efficacy and safety of HPMC used in the treatment of DED. Literature searches were conducted in PubMed and Cochrane CENTRAL. A total of 28 clinical trials from 26 publications are included in this review, including 21 clinical intervention studies evaluating the effect of HPMC treatment over time and seven single instillation studies evaluating the short‐term physical and symptomatic effects of HPMC after drop‐instillation. The duration of clinical intervention studies ranged from 2 weeks to 5.5 months. DED severity ranged from mild to severe. Drop frequency ranged from two to up to 16 drops per day. HPMC concentration in artificial tears ranged from 0.2% to 0.5%. No major complications or adverse events were reported. Artificial tears containing HPMC were effective at improving symptoms and some signs of DED. However, combination drops with HPMC plus other therapeutic ingredients seem more effective than HPMC alone. HPMC appears to be equally effective or inferior to hyaluronic acid (HA). There is no evidence of superiority or inferiority to either carboxymethylcellulose (CMC) or polyethylene glycol 400/propylene glycol (PEG/PG). No single study explained the choice of drop frequency or HPMC concentration. More well‐designed studies are needed to determine an evidence‐based standard for HPMC treatment, including drop frequency, concentration and molecular weight for different DED severity and subgroups.</description><identifier>ISSN: 1755-375X</identifier><identifier>ISSN: 1755-3768</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/aos.16753</identifier><identifier>PMID: 39219040</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>artificial tears ; Carboxymethylcellulose ; Cellulose ; Clinical trials ; DED ; dry eye disease ; Dry Eye Syndromes - diagnosis ; Dry Eye Syndromes - drug therapy ; Eye diseases ; HPMC ; Humans ; Hyaluronic acid ; hydroxypropyl methylcellulose ; hypromellose ; Hypromellose Derivatives ; Lubricant Eye Drops - administration &amp; dosage ; Medical treatment ; Methylcellulose ; Molecular weight ; Polyethylene glycol ; Propylene glycol ; Quality of Life ; Reviews ; Tears</subject><ispartof>Acta ophthalmologica (Oxford, England), 2024-12, Vol.102 (8), p.881-896</ispartof><rights>2024 The Author(s). published by John Wiley &amp; Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.</rights><rights>2024 The Author(s). Acta Ophthalmologica published by John Wiley &amp; Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2783-1640c07fd67d3d539f8bc2ae8e662e299d2b61ff7fd3e16edd2ccacfca7b39673</cites><orcidid>0000-0002-7762-831X ; 0000-0003-2804-7399 ; 0000-0002-2276-1770</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faos.16753$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faos.16753$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39219040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mysen, O. Martin B.</creatorcontrib><creatorcontrib>Hynnekleiv, Leif</creatorcontrib><creatorcontrib>Magnø, Morten S.</creatorcontrib><creatorcontrib>Vehof, Jelle</creatorcontrib><creatorcontrib>Utheim, Tor P.</creatorcontrib><title>Review of Hydroxypropyl Methylcellulose in Artificial Tears for the Treatment of Dry Eye Disease</title><title>Acta ophthalmologica (Oxford, England)</title><addtitle>Acta Ophthalmol</addtitle><description>Dry eye disease (DED) is a highly prevalent condition, resulting in reduced quality of life, lower participation in social life and impaired work efficiency. Hydroxypropyl methylcellulose (HPMC) is a cellulose‐based viscosity‐enhancing agent and is one of the most popular therapeutic ingredients in artificial tears. This review aims to evaluate the literature on the efficacy and safety of HPMC used in the treatment of DED. Literature searches were conducted in PubMed and Cochrane CENTRAL. A total of 28 clinical trials from 26 publications are included in this review, including 21 clinical intervention studies evaluating the effect of HPMC treatment over time and seven single instillation studies evaluating the short‐term physical and symptomatic effects of HPMC after drop‐instillation. The duration of clinical intervention studies ranged from 2 weeks to 5.5 months. DED severity ranged from mild to severe. Drop frequency ranged from two to up to 16 drops per day. HPMC concentration in artificial tears ranged from 0.2% to 0.5%. No major complications or adverse events were reported. Artificial tears containing HPMC were effective at improving symptoms and some signs of DED. However, combination drops with HPMC plus other therapeutic ingredients seem more effective than HPMC alone. HPMC appears to be equally effective or inferior to hyaluronic acid (HA). There is no evidence of superiority or inferiority to either carboxymethylcellulose (CMC) or polyethylene glycol 400/propylene glycol (PEG/PG). No single study explained the choice of drop frequency or HPMC concentration. More well‐designed studies are needed to determine an evidence‐based standard for HPMC treatment, including drop frequency, concentration and molecular weight for different DED severity and subgroups.</description><subject>artificial tears</subject><subject>Carboxymethylcellulose</subject><subject>Cellulose</subject><subject>Clinical trials</subject><subject>DED</subject><subject>dry eye disease</subject><subject>Dry Eye Syndromes - diagnosis</subject><subject>Dry Eye Syndromes - drug therapy</subject><subject>Eye diseases</subject><subject>HPMC</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>hydroxypropyl methylcellulose</subject><subject>hypromellose</subject><subject>Hypromellose Derivatives</subject><subject>Lubricant Eye Drops - administration &amp; dosage</subject><subject>Medical treatment</subject><subject>Methylcellulose</subject><subject>Molecular weight</subject><subject>Polyethylene glycol</subject><subject>Propylene glycol</subject><subject>Quality of Life</subject><subject>Reviews</subject><subject>Tears</subject><issn>1755-375X</issn><issn>1755-3768</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kEtLAzEUhYMoWqsL_4AE3OiiNY9OMrMsbX2AImgFdzHN3GDKtKnJjDr_3tSqC8GzuXfx8XE4CB1R0qcp59rHPhUy41uoQ2WW9bgU-fbvnz3tof0Y54QIKsRgF-3xgtGCDEgHPd_Dm4N37C2-asvgP9pV8Ku2wrdQv7SVgapqKh8BuyUehtpZZ5yu8BR0iNj6gOsXwNMAul7Asl5rxqHFkxbw2EXQEQ7QjtVVhMPv20WPF5Pp6Kp3c3d5PRre9AyTOe9RMSCGSFsKWfIy44XNZ4ZpyEEIBqwoSjYT1NpEcKACypIZo401Ws54ISTvotONN_V_bSDWauHiur5egm-i4qQo8kymJPTkDzr3TVimdopTJqRkGaGJOttQJvgYA1i1Cm6hQ6soUevZVZpdfc2e2ONvYzNbQPlL_uycgPMN8O4qaP83qeHdw0b5Cfr-jN0</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Mysen, O. Martin B.</creator><creator>Hynnekleiv, Leif</creator><creator>Magnø, Morten S.</creator><creator>Vehof, Jelle</creator><creator>Utheim, Tor P.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7762-831X</orcidid><orcidid>https://orcid.org/0000-0003-2804-7399</orcidid><orcidid>https://orcid.org/0000-0002-2276-1770</orcidid></search><sort><creationdate>202412</creationdate><title>Review of Hydroxypropyl Methylcellulose in Artificial Tears for the Treatment of Dry Eye Disease</title><author>Mysen, O. Martin B. ; Hynnekleiv, Leif ; Magnø, Morten S. ; Vehof, Jelle ; Utheim, Tor P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2783-1640c07fd67d3d539f8bc2ae8e662e299d2b61ff7fd3e16edd2ccacfca7b39673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>artificial tears</topic><topic>Carboxymethylcellulose</topic><topic>Cellulose</topic><topic>Clinical trials</topic><topic>DED</topic><topic>dry eye disease</topic><topic>Dry Eye Syndromes - diagnosis</topic><topic>Dry Eye Syndromes - drug therapy</topic><topic>Eye diseases</topic><topic>HPMC</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>hydroxypropyl methylcellulose</topic><topic>hypromellose</topic><topic>Hypromellose Derivatives</topic><topic>Lubricant Eye Drops - administration &amp; dosage</topic><topic>Medical treatment</topic><topic>Methylcellulose</topic><topic>Molecular weight</topic><topic>Polyethylene glycol</topic><topic>Propylene glycol</topic><topic>Quality of Life</topic><topic>Reviews</topic><topic>Tears</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mysen, O. Martin B.</creatorcontrib><creatorcontrib>Hynnekleiv, Leif</creatorcontrib><creatorcontrib>Magnø, Morten S.</creatorcontrib><creatorcontrib>Vehof, Jelle</creatorcontrib><creatorcontrib>Utheim, Tor P.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles(OpenAccess)</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mysen, O. Martin B.</au><au>Hynnekleiv, Leif</au><au>Magnø, Morten S.</au><au>Vehof, Jelle</au><au>Utheim, Tor P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of Hydroxypropyl Methylcellulose in Artificial Tears for the Treatment of Dry Eye Disease</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><addtitle>Acta Ophthalmol</addtitle><date>2024-12</date><risdate>2024</risdate><volume>102</volume><issue>8</issue><spage>881</spage><epage>896</epage><pages>881-896</pages><issn>1755-375X</issn><issn>1755-3768</issn><eissn>1755-3768</eissn><abstract>Dry eye disease (DED) is a highly prevalent condition, resulting in reduced quality of life, lower participation in social life and impaired work efficiency. Hydroxypropyl methylcellulose (HPMC) is a cellulose‐based viscosity‐enhancing agent and is one of the most popular therapeutic ingredients in artificial tears. This review aims to evaluate the literature on the efficacy and safety of HPMC used in the treatment of DED. Literature searches were conducted in PubMed and Cochrane CENTRAL. A total of 28 clinical trials from 26 publications are included in this review, including 21 clinical intervention studies evaluating the effect of HPMC treatment over time and seven single instillation studies evaluating the short‐term physical and symptomatic effects of HPMC after drop‐instillation. The duration of clinical intervention studies ranged from 2 weeks to 5.5 months. DED severity ranged from mild to severe. Drop frequency ranged from two to up to 16 drops per day. HPMC concentration in artificial tears ranged from 0.2% to 0.5%. No major complications or adverse events were reported. Artificial tears containing HPMC were effective at improving symptoms and some signs of DED. However, combination drops with HPMC plus other therapeutic ingredients seem more effective than HPMC alone. HPMC appears to be equally effective or inferior to hyaluronic acid (HA). There is no evidence of superiority or inferiority to either carboxymethylcellulose (CMC) or polyethylene glycol 400/propylene glycol (PEG/PG). No single study explained the choice of drop frequency or HPMC concentration. More well‐designed studies are needed to determine an evidence‐based standard for HPMC treatment, including drop frequency, concentration and molecular weight for different DED severity and subgroups.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39219040</pmid><doi>10.1111/aos.16753</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-7762-831X</orcidid><orcidid>https://orcid.org/0000-0003-2804-7399</orcidid><orcidid>https://orcid.org/0000-0002-2276-1770</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1755-375X
ispartof Acta ophthalmologica (Oxford, England), 2024-12, Vol.102 (8), p.881-896
issn 1755-375X
1755-3768
1755-3768
language eng
recordid cdi_proquest_miscellaneous_3099857777
source Wiley-Blackwell Journals; MEDLINE
subjects artificial tears
Carboxymethylcellulose
Cellulose
Clinical trials
DED
dry eye disease
Dry Eye Syndromes - diagnosis
Dry Eye Syndromes - drug therapy
Eye diseases
HPMC
Humans
Hyaluronic acid
hydroxypropyl methylcellulose
hypromellose
Hypromellose Derivatives
Lubricant Eye Drops - administration & dosage
Medical treatment
Methylcellulose
Molecular weight
Polyethylene glycol
Propylene glycol
Quality of Life
Reviews
Tears
title Review of Hydroxypropyl Methylcellulose in Artificial Tears for the Treatment of Dry Eye Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A44%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20Hydroxypropyl%20Methylcellulose%20in%20Artificial%20Tears%20for%20the%20Treatment%20of%20Dry%20Eye%20Disease&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=Mysen,%20O.%20Martin%20B.&rft.date=2024-12&rft.volume=102&rft.issue=8&rft.spage=881&rft.epage=896&rft.pages=881-896&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/aos.16753&rft_dat=%3Cproquest_cross%3E3099857777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3126772501&rft_id=info:pmid/39219040&rfr_iscdi=true